Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques

Molecular Therapy

Volumn 19, Issue 2, 2011, Pages 417-426

  Lasaro, Marcio O ^a   Haut, Larissa H ^a,b   Zhou, Xiangyang ^a   Xiang, Zhiquan ^a   Zhou, Dongming ^a   Li, Yan ^a   Giles Davis, Wynetta ^a   Li, Hua ^a   Engram, Jessica C ^c   Dimenna, Lauren J ^a   Bian, Ang ^a   Sazanovich, Marina ^a   Parzych, Elizabeth M ^a   Kurupati, Raj ^a   Small, Juliana C ^a   Wu, Te Lang ^a   Leskowitz, Rachel M ^a   Klatt, Nicole R ^d   Brenchley, Jason M ^d   Garber, David A ^e   Lewis, Mark ^f   Ratcliffe, Sarah J ^g   Betts, Michael R ^c   Silvestri, Guido ^c,e   Ertl, Hildegund C ^a   more..

^a WISTAR INSTITUTE   (United States)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BIOQUAL INC   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD28 ANTIGEN; CHEMOKINE RECEPTOR CCR7; FAS ANTIGEN; GAG PROTEIN; GAMMA INTERFERON; INTERLEUKIN 2; L SELECTIN; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; NEUTRALIZING ANTIBODY; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFICACY; FEMALE; HAPLOTYPE; MALE; MORTALITY; NONHUMAN; OVERALL SURVIVAL; RHESUS MONKEY; SEROTYPE; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS INFECTION; T LYMPHOCYTE; VACCINATION; VIRUS INFECTION; VIRUS LOAD;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; PAN; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 79551653511     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.238     Document Type: Article

References (32)

1. Rerks-Ngarm, S, Pitisuttithum, P, Nitayaphan, S, Kaewkungwal, J, Chiu, J, Paris, R et al. (2009). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
2. Buchbinder, SP, Mehrotra, DV, Duerr, A, Fitzgerald, DW, Mogg, R, Li, D et al. (2008). Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
3. McElrath, MJ, De Rosa, SC, Moodie, Z, Dubey, S, Kierstead, L, Janes, H et al. (2008). HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372: 1894-1905.
4. Burton, DR, Stanfield, RL and Wilson, IA (2005). Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci USA 102: 14943-14948.
5. Haut, LH and Ertl, HC (2009). Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine. J Leukoc Biol 86: 779-793.
6. Korber, BT, Letvin, NL and Haynes, BF (2009). T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol 83: 8300-8314.
7. Baker, BM, Block, BL, Rothchild, AC and Walker, BD (2009). Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther 9: 55-69.
8. Pereyra, F, Addo, MM, Kaufmann, DE, Liu, Y, Miura, T, Rathod, A et al. (2008). Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 197: 563-571.
9. Liu, J, O'Brien, KL, Lynch, DM, Simmons, NL, La Porte, A, Riggs, AM et al. (2009). Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457: 87-91.
10. Shiver, JW, Fu, TM, Chen, L, Casimiro, DR, Davies, ME, Evans, RK et al. (2002). Replication-incompetent adenoviral vaccine vector elicits effective antiimmunodeficiency- virus immunity. Nature 415: 331-335.
11. Jin, X, Bauer, DE, Tuttleton, SE, Lewin, S, Gettie, A, Blanchard, J et al. (1999). Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189: 991-998.
12. Schmitz, JE, Johnson, RP, McClure, HM, Manson, KH, Wyand, MS, Kuroda, MJ et al. (2005). Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3- vaccinated rhesus macaques. J Virol 79: 8131-8141.
13. Pinto, AR, Fitzgerald, JC, Giles-Davis, W, Gao, GP, Wilson, JM and Ertl, HC (2003). Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol 171: 6774-6779.
14. Tatsis, N, Lasaro, MO, Lin, SW, Haut, LH, Xiang, ZQ, Zhou, D et al. (2009). Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens. J Immunol 182: 6587-6599.
15. Casimiro, DR, Wang, F, Schleif, WA, Liang, X, Zhang, ZQ, Tobery, TW et al. (2005). Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 79: 15547-15555.
16. Chen, H, Xiang, ZQ, Li, Y, Kurupati, RK, Jia, B, Bian, A et al. (2010). Adenovirus-based vaccines: comparison of vectors from three families of adenovirideae. J Virol 84: 10522-10532.
17. Farina, SF, Gao, GP, Xiang, ZQ, Rux, JJ, Burnett, RM, Alvira, MR et al. (2001). Replication-defective vector based on a chimpanzee adenovirus. J Virol 75: 11603-11613.
18. Xiang, Z, Li, Y, Cun, A, Yang, W, Ellenberg, S, Switzer, WM et al. (2006). Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerging Infect Dis 12: 1596-1599.
19. Engram, JC, Dunham, RM, Makedonas, G, Vanderford, TH, Sumpter, B, Klatt, NR et al. (2009). Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression. J Immunol 183: 706-717.
20. Haut, L, Lin, S, Tatsis, N, DiMenna, L, Giles-Davis, W, Pinto, A et al. (in press). Robust genital gag-specific CD8+ T-cell responses in mice upon intramuscular immunization with simian adenoviral vectors expressing HIV-1-gag. Eur J Immunol .
21. Day, CL, Kaufmann, DE, Kiepiela, P, Brown, JA, Moodley, ES, Reddy, S et al. (2006). PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354.
22. Velu, V, Kannanganat, S, Ibegbu, C, Chennareddi, L, Villinger, F, Freeman, GJ et al. (2007). Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination. J Virol 81: 5819-5828.
23. Pal, R, Venzon, D, Letvin, NL, Santra, S, Montefiori, DC, Miller, NR et al. (2002). ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol 76: 292-302.
24. Loffredo, JT, Friedrich, TC, León, EJ, Stephany, JJ, Rodrigues, DS, Spencer, SP et al. (2007). CD8+ T cells from SIV elite controller macaques recognize Mamu-B*08-bound epitopes and select for widespread viral variation. PLoS ONE 2: e1152.
25. Yant, LJ, Friedrich, TC, Johnson, RC, May, GE, Maness, NJ, Enz, AM et al. (2006). The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol 80: 5074-5077.
26. Hansen, SG, Vieville, C, Whizin, N, Coyne-Johnson, L, Siess, DC, Drummond, DD et al. (2009). Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15: 293-299.
27. Wilson, NA, Keele, BF, Reed, JS, Piaskowski, SM, MacNair, CE, Bett, AJ et al. (2009). Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol 83: 6508-6521.
28. Barouch, DH, Liu, J, Lynch, DM, O'Brien, KL, La Porte, A, Simmons, NL et al. (2009). Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J Virol 83: 9584-9590.
29. Abbink, P, Lemckert, AA, Ewald, BA, Lynch, DM, Denholtz, M, Smits, S et al. (2007). Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81: 4654-4663.
30. Fitzgerald, JC, Gao, GP, Reyes-Sandoval, A, Pavlakis, GN, Xiang, ZQ, Wlazlo, AP et al. (2003). A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 170: 1416-1422.
31. Xiang, Z, Gao, G, Reyes-Sandoval, A, Cohen, CJ, Li, Y, Bergelson, JM et al. (2002). Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 76: 2667-2675.
32. Kaufman, CL, Gaines, BA and Ildstad, ST (1995). Xenotransplantation. Annu Rev Immunol 13: 339-367.